NCT02232516 - Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 11, 2015

Primary Completion Date

August 11, 2020

Study Completion Date

August 31, 2024

Conditions

Adult Nasal Type Extranodal NK/T-cell LymphomaAnaplastic Large Cell LymphomaAngioimmunoblastic T-cell LymphomaHepatosplenic T-cell LymphomaPeripheral T-cell LymphomaStage I Cutaneous T-cell Non-Hodgkin LymphomaStage IA Mycosis Fungoides/Sezary SyndromeStage IB Mycosis Fungoides/Sezary SyndromeStage II Cutaneous T-cell Non-Hodgkin LymphomaStage IIA Mycosis Fungoides/Sezary SyndromeStage IIB Mycosis Fungoides/Sezary SyndromeStage III Cutaneous T-cell Non-Hodgkin LymphomaStage IIIA Mycosis Fungoides/Sezary SyndromeStage IIIB Mycosis Fungoides/Sezary SyndromeStage IV Cutaneous T-cell Non-Hodgkin LymphomaStage IVA Mycosis Fungoides/Sezary SyndromeStage IVB Mycosis Fungoides/Sezary Syndrome

Interventions

DRUG

romidepsin

Given IV

DRUG

lenalidomide

Given PO

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (5)

10021

Weill Cornell Medicine, New York

60611

Northwestern University, Chicago

91010

City of Hope, Duarte

98109

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle

06520

Yale University, New Haven